BLGO
BioLargo, Inc.0.1800
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
56.59MP/E (TTM)
-Basic EPS (TTM)
-0.03Dividend Yield
0%Recent Filings
8-K
10-K
8-K
Officers convert pay to locked shares
BioLargo officers converted $99,901 in unpaid salary and expenses into 624,383 common shares at $0.16 on November 14, 2025. Shares lock up until the company hits $40 million quarterly/annual gross revenue, $300 million market cap, or change of control. This aligns officer incentives with growth milestones.
10-Q
Q3 FY2025 results
BioLargo's Q3 revenue plunged 75% y/y to $1.1M (derived), crushed by Pooph customer defaults that triggered a $3.8M credit loss expense—now in litigation over patent infringement and unpaid royalties. Gross profit dived to $0.4M from $1.7M, while operating loss ballooned to $7.2M versus $1.1M y/y, driven by that one-time hit and higher SG&A. Cash climbed to $4.5M on $7.3M financing inflows, topping $3.4M operating cash burn, yet working capital sits at $2.3M amid going concern warnings. Pooph was 64% of YTD revenue. Debt remains modest at $0.3M. Customer concentration bites hard.
BCHT
Birchtech Corp.
0.89+0.01
BIOF
Blue Biofuels Inc.
0.17-0.01
BKTH
Breakthrough Chemistry Inc.
0.17+0.00
BLFS
BioLife Solutions, Inc.
24.61-0.04
BSLK
Bolt Projects Holdings, Inc.
1.81-0.01
FBLG
FibroBiologics, Inc.
0.24-0.02
FF
FutureFuel Corp.
3.34-0.01
GOGR
Go Green Global Technologies Co
0.04+0.00
LGO
Largo Inc.
0.94-0.02
LNZA
LanzaTech Global, Inc.
13.10-1.33